Trevi to Discuss Haduvio Cough Data on February 25 at Oppenheimer Conference
Trevi Therapeutics CEO Jennifer Good and CFO David Hastings will host a virtual fireside chat and investor meetings on February 25 at 9:20 a.m. ET at the Oppenheimer Healthcare Life Sciences Conference. Haduvio™ reduced cough frequency statistically significantly in IPF and RCC trials, addressing about 530,000 U.S. patients.
1. Conference Participation
Jennifer Good, President and CEO, and David Hastings, CFO, will deliver a fireside chat at 9:20 a.m. ET on February 25 during the Oppenheimer 36th Annual Healthcare Life Sciences Conference and conduct virtual investor meetings, providing opportunities for insight into Trevi’s development strategy and financial positioning.
2. Haduvio Clinical Data
Haduvio™ (oral nalbuphine ER) has demonstrated statistically significant reductions in cough frequency in idiopathic pulmonary fibrosis and refractory chronic cough trials, acting as a kappa agonist/mu antagonist on the cough reflex arc and representing the first investigational therapy to achieve such results.
3. Market Opportunity
Chronic cough in IPF and non-IPF ILD affects approximately 150,000 and 228,000 U.S. patients respectively, with 50–67% experiencing uncontrolled symptoms, and refractory chronic cough impacts 2–3 million patients, underscoring Haduvio’s potential to address high unmet needs across a combined patient base of roughly 530,000.